Sera Prognostics (NASDAQ:SERA) Stock Rating Upgraded by Jefferies Financial Group

Sera Prognostics (NASDAQ:SERA) was upgraded by investment analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Other research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research report on Monday. Wall Street Zen upgraded shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Sera Prognostics has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Sera Prognostics Price Performance

Shares of NASDAQ:SERA opened at $3.56 on Monday. The company has a market capitalization of $137.40 million, a P/E ratio of -4.62 and a beta of 0.97. Sera Prognostics has a 1-year low of $1.37 and a 1-year high of $9.13. The firm’s 50 day simple moving average is $3.20 and its two-hundred day simple moving average is $2.85.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Sera Prognostics had a negative return on equity of 41.69% and a negative net margin of 34,343.16%.The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.10 million. On average, sell-side analysts anticipate that Sera Prognostics will post -0.96 earnings per share for the current fiscal year.

Insider Activity at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 28,215 shares of the stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $3.04, for a total value of $85,773.60. Following the sale, the chief executive officer directly owned 768,081 shares in the company, valued at approximately $2,334,966.24. This represents a 3.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 50,587 shares of company stock worth $157,528 over the last quarter. Corporate insiders own 15.80% of the company’s stock.

Institutional Trading of Sera Prognostics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC increased its stake in shares of Sera Prognostics by 8.9% during the third quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock valued at $285,000 after buying an additional 7,643 shares during the period. Abel Hall LLC purchased a new stake in shares of Sera Prognostics during the 2nd quarter valued at $31,000. Wagner Wealth Management LLC purchased a new stake in Sera Prognostics in the second quarter valued at about $34,000. Citadel Advisors LLC raised its position in shares of Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after purchasing an additional 12,439 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Sera Prognostics in the 3rd quarter worth approximately $38,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.